BlackRock’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-26,558
Closed -$15.4K 5687
2023
Q1
$15.4K Hold
26,558
﹤0.01% 5280
2022
Q4
$18.7K Sell
26,558
-1
-0% -$2 ﹤0.01% 5387
2022
Q3
$74K Hold
26,559
﹤0.01% 5267
2022
Q2
$121K Sell
26,559
-15,424
-37% -$67.7K ﹤0.01% 5186
2022
Q1
$301K Sell
41,983
-750
-2% -$4.36K ﹤0.01% 5015
2021
Q4
$288K Buy
42,733
+641
+2% +$6.56K ﹤0.01% 5017
2021
Q3
$490K Sell
42,092
-334
-0.8% -$4.62K ﹤0.01% 4756
2021
Q2
$794K Buy
42,426
+9,497
+29% +$177K ﹤0.01% 4579
2021
Q1
$764K Buy
32,929
+25,596
+349% +$648K ﹤0.01% 4548
2020
Q4
$102K Hold
7,333
﹤0.01% 4582
2020
Q3
$152K Hold
7,333
﹤0.01% 4454
2020
Q2
$111K Hold
7,333
﹤0.01% 4475
2020
Q1
$101K Hold
7,333
﹤0.01% 4349
2019
Q4
$219K Buy
7,333
+7,282
+14,278% +$174K ﹤0.01% 4304
2019
Q3
$1K Buy
51
+3
+6% +$58 ﹤0.01% 4955
2019
Q2
$1K Buy
48
+4
+9% +$125 ﹤0.01% 4998
2019
Q1
$2K Buy
44
+3
+7% +$123 ﹤0.01% 4846
2018
Q4
$1K Buy
41
+4
+11% +$337 ﹤0.01% 4929
2018
Q3
$6K Buy
37
+1
+3% +$148 ﹤0.01% 4793
2018
Q2
$5K Sell
36
-263
-88% -$39.8K ﹤0.01% 4836
2018
Q1
$74K Sell
299
-6
-2% -$1.69K ﹤0.01% 4389
2017
Q4
$85K Buy
305
+33
+12% +$12.6K ﹤0.01% 4361
2017
Q3
$110K Sell
272
-10
-4% -$5.21K ﹤0.01% 4352
2017
Q2
$168K Buy
282
+11
+4% +$6.43K ﹤0.01% 4299
2017
Q1
$167K Buy
+271
New +$96.4K ﹤0.01% 4252
2014
Q2
Hold
0
3241
2014
Q1
Hold
0
3180

Other funds holding VYNT

BlackRock's VYNT Position: Q2 2023 in Review

BlackRock sold out of Vyant Bio, Inc. Common Stock (VYNT) in Q2 2023, closing a stake of 26,558 shares — an estimated $15.4K sold.

BlackRock first reported a position in VYNT in Q1 2017 and held it in 25 quarters. The position peaked at $794K in Q2 2021. 1 fund tracked by Wall St. Rank holds VYNT as of Q2 2023.

  • BlackRock reported no remaining Vyant Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • BlackRock sold 26,558 Vyant Bio, Inc. Common Stock shares in Q2 2023, an estimated $15.4K.
  • BlackRock first reported a position in Vyant Bio, Inc. Common Stock in Q1 2017 and held it in 25 quarters.
  • BlackRock's Vyant Bio, Inc. Common Stock position peaked at $794K in Q2 2021.
  • 1 fund tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q2 2023.

Based on BlackRock's 13F filing for Q2 2023, filed 11 Aug 2023.